Addressing Disparities in Triple-Negative Breast Cancer Care

Study researchers examined the social and economic disparities in the use of immunotherapy for treating triple-negative breast cancer (TNBC) in the United States. TNBC is a particularly aggressive form of breast cancer with limited treatment options. The study aimed to identify barriers that prevent equitable access to immune checkpoint inhibitors (ICIs), a type of immunotherapy, among different racial, socioeconomic, and geographic groups.

This significant research addresses the unequal access to life-saving treatments for TNBC, which disproportionately affects marginalized communities. Understanding these disparities is crucial for healthcare providers, policymakers, and the academic community to develop strategies that ensure all patients, regardless of their background, have equal access to effective treatments. By highlighting these inequities, the study aims to improve health outcomes and survival rates for underrepresented groups.

The researchers conducted a narrative review of literature from 2000 to 2025, using databases including PubMed, MEDLINE, and Google Scholar. They focused on studies involving clinical trials, observational cohorts, and reviews that discussed trial participation, biomarker testing, treatment initiation, adherence, and outcomes. The review paid particular attention to disparities related to race, ethnicity, insurance status, and geographic location.

The study found that ICIs, or inhibitors, improve survival rates for some TNBC patients. However, Black, Hispanic, and rural patients are often underrepresented in clinical trials, which limits the applicability of trial results. Disparities in testing for biomarkers, which are substances that indicate the presence of cancer, and issues with insurance coverage and access to specialized cancer centers worsen these inequities. Despite these challenges, when marginalized patients receive ICIs, their outcomes are similar to those of more privileged groups.

The findings suggest that addressing social and economic barriers could lead to more equitable health outcomes for TNBC patients. Ensuring diverse clinical trial participation, standardizing biomarker testing, and expanding insurance coverage are crucial steps. These measures could transform the delivery of immunotherapy and improve survival rates across all demographics.

The authors recommend future research to combine precision oncology, which tailors treatment based on individual genetic information, with approaches that consider social factors. This could help ensure that new immunotherapies benefit all patients, not just those with better access to healthcare. Addressing both biological and systemic disparities is essential for achieving fair outcomes in TNBC treatment.

Yale University provided funding and support for the research.